Financhill
Sell
50

CATX Quote, Financials, Valuation and Earnings

Last price:
$3.9500
Seasonality move :
8730.09%
Day range:
$3.7500 - $4.1880
52-week range:
$1.6000 - $16.5500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
27.49x
P/B ratio:
1.02x
Volume:
1.7M
Avg. volume:
1.6M
1-year change:
-68.4%
Market cap:
$289.5M
Revenue:
--
EPS (TTM):
-$1.25

Analysts' Opinion

  • Consensus Rating
    Perspective Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $14.1071, Perspective Therapeutics has an estimated upside of 261.72% from its current price of $3.9000.
  • Price Target Downside
    According to analysts, the lowest downside price target is $6.0000 representing 100% downside risk from its current price of $3.9000.

Fair Value

  • According to the consensus of 11 analysts, Perspective Therapeutics has 261.72% upside to fair value with a price target of $14.1071 per share.

CATX vs. S&P 500

  • Over the past 5 trading days, Perspective Therapeutics has overperformed the S&P 500 by 11.13% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Perspective Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Perspective Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Perspective Therapeutics reported revenues of --.

Earnings Growth

  • Perspective Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Perspective Therapeutics reported earnings per share of -$0.25.
Enterprise value:
79.5M
EV / Invested capital:
--
Price / LTM sales:
27.49x
EV / EBIT:
--
EV / Revenue:
7.99x
PEG ratio (5yr expected):
-0.33x
EV / Free cash flow:
-0.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $9M -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$17.4M -$44.2M -$75.6M -$13M -$21.8M
EBITDA -$16.7M -$41.3M -$84M -$11.4M -$17.3M
Diluted EPS -$0.50 -$5.23 -$1.25 -$0.25 -$0.25
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $68.1M $62.8M $40.3M $188.2M $215.7M
Total Assets $71.3M $66.1M $127.6M $278.3M $329.3M
Current Liabilities $1.9M $2M $7.2M $14.5M $12.7M
Total Liabilities $3.2M $2.9M $9.6M $48.4M $44.7M
Total Equity $68.1M $63.2M $118M $229.9M $284.6M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$15.8M -$13.3M -$53.7M $13.8M -$21.6M
Cash From Investing -$10.1M -$48.2M -$177.2M -$47.3M -$5.6M
Cash From Financing -$52K $167.2M $133M $166.3M $10M
Free Cash Flow -$16.2M -$23.3M -$103.7M $4.8M -$26.2M
CATX
Sector
Market Cap
$289.5M
$34.5M
Price % of 52-Week High
23.57%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-68.4%
-35.15%
Beta (5-Year)
1.177
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $3.8075
200-day SMA
Sell
Level $4.7688
Bollinger Bands (100)
Buy
Level 2.1177 - 3.3177
Chaikin Money Flow
Sell
Level -48.5M
20-day SMA
Buy
Level $3.6870
Relative Strength Index (RSI14)
Buy
Level 58.4743
ADX Line
Buy
Level 30.6449
Williams %R
Neutral
Level -33.9713
50-day SMA
Buy
Level $3.0980
MACD (12, 26)
Buy
Level 0.2247
25-day Aroon Oscillator
Buy
Level 24
On Balance Volume
Neutral
Level 69.5M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Stock Forecast FAQ

In the current month, CATX has received 10 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $14.1071.

  • Where Will Perspective Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Perspective Therapeutics share price will rise to $14.1071 per share over the next 12 months.

  • What Do Analysts Say About Perspective Therapeutics?

    Analysts are divided on their view about Perspective Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics is a Sell and believe this share price will drop from its current level to $6.0000.

  • What Is Perspective Therapeutics's Price Target?

    The price target for Perspective Therapeutics over the next 1-year time period is forecast to be $14.1071 according to 11 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is CATX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Perspective Therapeutics is a Buy. 10 of 11 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CATX?

    You can purchase shares of Perspective Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics shares.

  • What Is The Perspective Therapeutics Share Price Today?

    Perspective Therapeutics was last trading at $3.9500 per share. This represents the most recent stock quote for Perspective Therapeutics. Yesterday, Perspective Therapeutics closed at $3.9000 per share.

  • How To Buy Perspective Therapeutics Stock Online?

    In order to purchase Perspective Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
71
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
61
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
78
SBET alert for Jul 16

SharpLink Gaming [SBET] is up 30.48% over the past day.

Buy
75
MP alert for Jul 16

MP Materials [MP] is up 0.43% over the past day.

Sell
38
NAIL alert for Jul 16

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 0.74% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock